Estados Unidos · Plataformas y datos · MarketBeat
Ocular Therapeutix Targets Q4 FDA Filing for AXPAXLI After Key Trial Win

Resumen detallado
Ocular Therapeutix (NASDAQ:OCUL) remains on track to submit a U.S. marketing application this quarter for AXPAXLI, its experimental treatment for wet age-related macular degeneration, CEO Pravin Dugel said at the UBS Global Biopharma Conference in London. Dugel said the planned application will rel
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)




